Abstract
Dipeptidyl peptidase 9 (DPP9) is a direct inhibitor of NLRP1, but how it impacts inflammasome regulation in vivo is not yet established. Here, we report two families with immune-associated defects, skin pigmentation abnormalities and neurological deficits that segregate with biallelic DPP9 rare variants. Using patient-derived primary cells and biochemical assays, these variants are shown to behave as hypomorphic or loss-of-function alleles that fail to repress NLRP1. Remarkably, the removal in mice, of a single copy of either Nlrp1a/b/c, Asc, Gsdmd, Il-1r, but not Il-18, was sufficient to rescue the lethality of Dpp9 mutant neonates. These experiments suggest that the deleterious consequences of DPP9 deficiency are mostly driven by the aberrant activation of the canonical NLRP1 inflammasome and IL-1β signaling. Collectively, our results delineate a Mendelian disorder of DPP9 deficiency driven by increased NLRP1 activity as demonstrated in patient cells and in a mouse model of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a Strategic Positioning Fund for Genetic Orphan Diseases and an inaugural A*STAR Investigatorship from the Agency for Science, Technology and Research in Singapore. The Laboratory of Human Genetics of Infectious Diseases is supported by the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR001866), the French National Research Agency (ANR) under the Investments for the Future ANR program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the PNEUMOPID project (Grant ANR 14-CE15-0009-01), the French Foundation for Medical Research (FRM) (EQU201903007798), the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Sante et de la Recherche Medicale (INSERM), and the Universite de Paris. K.L. is supported by a NMRC Open Fund - Young Individual Research Grant (OFYIRG19MAY- 0039).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by A*STAR IRB (2019-087) and genetic analyses were performed in accordance with bioethics rules of national laws. Written informed consents were obtained from all the participants or their parents. The study was approved by and performed in accordance with the requirements of the institutional ethics committees of The Rockefeller University Hospital, New York, USA, and Necker-Enfants Malades Hospital, Paris, France. Informed consent was obtained for all patient and healthy control volunteers reported in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This second version is revised. It contains an updated co-author list and corrected results pertaining to blood immnuno-profiling experiments in mutant mice (Figure 3).
Data Availability
The data that support the findings of this study are available from the corresponding authors upon request.
